LifeTech Capital raised its StemCells STEM STEMD price target from $1.60 to $8 and maintained its Strong Speculative Buy rating in a research report published today.
In the report, LifeTech Capital states, "StemCells Inc. executed a 1:10 reverse split on July 6th and will trade under the symbol STEMD for the next 20 trading days. While the split-adjusted price will be attractive to institutions, we believe there could be an offsetting decrease in trading liquidity."
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in